Bruce E. Johnson, MD, on Evolving Challenges in Lung Cancer Drug Development

February 09, 2021 By The ASCO Post Staff

Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, offers his expert perspective on single-arm drug approvals for targeted agents between 2016 and 2020, the need for biomarker testing, and the societal costs of drug development (Abstract PL04.03).

Related Content